Quantitative and qualitative MDCT evaluations showed no detectable differences in predefined mandibular morphometric measures versus placebo after 1 or 2 onabotulinumtoxinA treatments for MMP over 1 year. Safety events were localized and consistent with drug mechanism. Late-emerging effects beyond 12 months cannot be excluded.
Mallya et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: